|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival显示文摘BACKGROUND: In a multidisciplinary conference patients with advanced non-resectable hepatocellular carcinoma (HCC) were stratified according to their clinical status and tumor extent to different regional modalities or to best supportive care. The present study evaluated all patients who were stratified to repeated transarterial chemoembolization (TACE) from 1999 until 2003 in terms of tumor response, toxicity, and survival. A moderate embolizing approach was chosen using a combination of degradable starch microspheres (DSM) and iodized oil (Lipiodol) in order to combine anti-tumoral efficiency and low toxicity. METHODS: Fourty-seven patients were followed up prospectively. TACE treatment consisted of cisplatin (50 mg/m2), doxorubicin (50 mg/m2), 450-900 mg DSM, and 5-30 ml Lipiodol. DSM and Lipiodol were administered according to tumor vascularization. Patient characteristics,toxicity, and complications were outlined. In multivariate regression analyses of pre-treatment variables from a prospective database, predictors for tumor response and survival after TACE were determined. RESULTS: 112 TACE courses were performed (2.4±1.5 courses per patient). Mean maximum tumor size was 75 (± 43) mm, in 68% there was bilobar disease. Best response to TACE treatment was: progressive disease (PD) 9%, stable disease (SD) 55%, partial remission (PR) 36%, and complete remission (CR) 0%. Multivariate regression analyses identified tumor size ≤75 mm, tumor number ≤5, and tumor hypervascularization as predictors for PR. The overall 1-, 2-, and 3-year-survival rates were 75%, 59%, and 41%, respectively, and the median survival was 26 months. Low α-fetoprotein levels (<400 ng/ml) (Odds ratio=3.3) and PR as best response to TACE (Odds ratio=6.7) were significantly associated with long term survival (>30 months, R2=36%). Grade 3 toxicity occurred in 7.1% (n=8), and grade 4 toxicity in 3.6% (n=4) of all courses in terms of reversible leukopenia and thrombocytopenia. The incidence of major complications was 5.4% (n=6). All complications were managed conservatively. The mortality within 6 weeks after TACE was 2.1% (one patient). CONCLUSIONS: DSM and Lipiodol were combined successfully in the palliative TACE treatment of advanced HCC resulting in high rates of tumor response and survival at limited toxicity. Favourable tumor response was associated with tumor extent and vascularization. TACE using DSM and Lipiodol can be considered a suitable palliative measure in patients who might not tolerate long acting embolizing agents. | Timm D Kirchhoff Joerg S Bleck Arne Dettmer Ajay Chavan Herbert Rosenthal Sonja Merkesdal Bernd Frericks Lars Zender Nisar P Malek Tim F Greten Stefan Kubicka Michael P Manns Michael Galanski | 2007 | Hepatobiliary & Pancreatic Diseases International2007，6，3： | 15 |
| 2 | Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma显示文摘瞄准:为病人评估经皮的乙醇注射(PEI ) 的治疗效果与先进, non-resectable HCC 与 transarterial chemoembolisation 的联合相比(不作声) 并且重复单个会议的 PEI,独自重复了单个会议的 PEI,重复不作声独自一个,或最好的支持的照顾。方法:在学习时期期间接受了 PEI 治疗的所有病人根据物理地位和肿瘤程度被包括并且成层到下列治疗形式之一:联合不作声并且重复单个会议的 PEI,独自重复了单个会议的 PEI,重复不作声独自一个,或最好的支持的照顾。包括Okuda分类,门静脉血栓的存在,腹水的存在,肿瘤的数字,最大的肿瘤直径,和假胆硷酯酶( CHE )的临床的参数的预示的价值,以及孩子呸上演, alpha-fetoprotein (法新社),发烧,复杂并发症的发生在这些组之间被估计并且比较。幸存用 Kaplan-Meier 被决定,多,变量回归分析。结果:所有病人的 1 年、 3 年的幸存是 73% 和 47% 。在亚群分析,联合不作声, PEI (1 ) 与更长的幸存被联系(1- , 3- , 5 年的幸存:90% , 52% ,和 43%) 与 PEI 治疗相比独自一个(2 )(1- , 3- , 5 年的幸存:65% , 50% ,和 37%) 。(3 ) 在起始的层化以后的第二等的 PEI 产出可比较的结果不作声(1- , 3- , 5 年的幸存:91% , 40% ,和 30%) 当在到最好的支持的照顾(4 ) 的层化以后的 PEI 与减少的幸存被联系时(1- , 3- , 5 年的幸存:50% , 23% , 12%) 。除了选择治疗形式,为更好的幸存的预言者是肿瘤数字(n <
5 ) ,肿瘤尺寸(<
5 厘米) ,在 PEI 前的没有腹水,和在 PEI 以后的稳定的假胆硷酯酶(P <
0.05 ) 。在在 PEI 以后的 2 wk 以内的死亡是 2.8%(n = 3 ) 。有 24 (8.9%) 主修在包括部分肝梗塞,焦点的肝坏死,和肝脓肿的 PEI 以后的复杂并发症。所有复杂并发症能非通过手术被管理。结论:重复单个会议的 PEI 在有以可接受、可管理的复杂并发症率的先进 HCC 的病人是有效的。病人们成层到联合不作声, PEI 能比那些独自成层到重复 PEI 期望更长的幸存。而且,有在好临床的地位的大或多重的肿瘤的病人可以也从联合获利不作声并且为第二等的 PEI 的再考虑。 | Arne Dettmer Timm D Kirchhoff Michael Gebel Lars Zender Nisar P Malek Bernhard Panning Ajay Chavan Herbert Rosenthal Stefan Kubicka Susanne Krusche Sonja Merkesdal Michael Galanski Michael P Manns Joerg S Bleck | 2006 | World Journal of Gastroenterology2006，12，23： | 14 |
| 3 | Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial显示文摘 | Michael P Manns John G McHutchison Stuart C Gordon Vinod K Rustgi Mitchell Shiffman Robert Reindollar Zachary D Goodman Kenneth Koury Mei-Hsiu Ling Janice K Albrecht | 2001 | The Lancet2001，，9286： | 4 |
| 4 | Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study显示文摘 | Laurent Beaugerie Nicole Brousse Anne Marie Bouvier Jean Frédéric Colombel Marc Lémann Jacques Cosnes Xavier Hébuterne Antoine Cortot Yoram Bouhnik Jean Pierre Gendre Tabassome Simon Marc Maynadié Olivier Hermine Jean Faivre Fabrice Carrat | 2009 | The Lancet . 2009 (9701)2009，，： | 4 |
| 5 | Status review of mercury control options for coal-fired power plants显示文摘 | John H Pavlish Everett A Sondreal Michael D Mann Edwin S Olson Kevin C Galbreath Dennis L Laudal Steven A Benson | 2003 | Fuel Processing Technology2003，，2： | 4 |
| 6 | Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial显示文摘 | Michael P Manns John G McHutchison Stuart C Gordon Vinod K Rustgi Mitchell Shiffman Robert Reindollar Zachary D Goodman Kenneth Koury Mei-Hsiu Ling Janice K Albrecht | 2001 | The Lancet . 2001 (9286)2001，，9286： | 4 |
| 7 | Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial显示文摘 | Michael P Manns John G McHutchison Stuart C Gordon Vinod K Rustgi Mitchell Shiffman Robert Reindollar Zachary D Goodman Kenneth Koury Mei-Hsiu Ling Janice K Albrecht | 2001 | 2001 (9286)2001，，9286： | 4 |
| 8 | European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease显示文摘 | J.F. Rahier S. Ben-Horin Y. Chowers C. Conlon P. De Munter G. D’Haens E. Domènech R. Eliakim A. Eser J. Frater M. Gassull M. Giladi A. Kaser M. Lémann T. Moreels A. Moschen R. Pollok W. Reinisch M. Schunter E.F. Stange H. Tilg G. Van Assche N. Viget B. Vu | 2009 | Journal of Crohn’s and Colitis2009，，2： | 3 |
| 9 | Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease显示文摘 | Laurent Peyrin–Biroulet Kiarash Khosrotehrani Fabrice Carrat Anne–Marie Bouvier Jean–Baptiste Chevaux Tabassome Simon Frank Carbonnel Jean–Frédéric Colombel Jean–Louis Dupas Philippe Godeberge Jean–Pierre Hugot Marc Lémann Stéphane Nahon Jean–Marc Sabaté | 2011 | Gastroenterology2011，，5： | 3 |
| 10 | <ce:link locator='fx1'/> A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis显示文摘 | Geert D’Haens William J. Sandborn Brian G. Feagan Karel Geboes Stephen B. Hanauer E. Jan Irvine Marc Lémann Philippe Marteau Paul Rutgeerts Jurgen Sch?lmerich Lloyd R. Sutherland | 2007 | Gastroenterology2007，，2： | 2 |
| 11 | The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management显示文摘 | A. Dignass G. Van Assche J.O. Lindsay M. Lémann J. S?derholm J.F. Colombel S. Danese A. D’Hoore M. Gassull F. Gomollón D.W. Hommes P. Michetti C. O’Morain T. ?resland A. Windsor E.F. Stange S.P.L. Travis | 2010 | Journal of Crohn’s and Colitis2010，，1： | 2 |
| 12 | A Randomized, Double-Blind, Controlled Withdrawal Trial in Crohn’s Disease Patients in Long-term Remission on Azathioprine显示文摘 | Marc Lémann Jean-Yves Mary Jean-Frédéric Colombel Bernard Duclos Jean-Claude Soule Eric Lerebours Robert Modigliani Yoram Bouhnik | 2005 | Gastroenterology2005，，7： | 2 |
| 13 | Load regulation of the properties of adult feline cardiocytes: growth induction by cellular deformation显示文摘 | Mann D L Kent R L Cooper G | 1989 | Circ Res1989，64，6： | 2 |
| 14 | A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn’s disease显示文摘 | Jean-Frédéric Colombel Marc Lémann Michel Cassagnou Yoram Bouhnik Bernard Duclos Jean-Louis Dupas Bertrand Notteghem Jean-Yves Mary | 1999 | The American Journal of Gastroenterology1999，，： | 2 |
| 15 | European evidence-based Consensus on the management of ulcerative colitis: Current management显示文摘 | S.P.L. Travis E.F. Stange M. Lémann T. ?resland W.A. Bemelman Y. Chowers J.F. Colombel G. D'Haens S. Ghosh P. Marteau W. Kruis N.J.McC. Mortensen F. Penninckx M. Gassull | 2008 | Journal of Crohn’s and Colitis2008，，1： | 2 |
| 16 | <ce:link locator='fx1'/> A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis显示文摘 | Geert D'Haens William J. Sandborn Brian G. Feagan Karel Geboes Stephen B. Hanauer E. Jan Irvine Marc Lémann Philippe Marteau Paul Rutgeerts Jurgen Sch?lmerich Lloyd R. Sutherland | 2007 | Gastroenterology2007，，2： | 2 |
| 17 | Casein kinase 2 is the major enzyme in brain that phosphorylates Ser129 of human alpha synuelein: Implication for alpha-synueleinopathies显示文摘 | ISHII A NONAKA T TANIGUCHI S SAOTO T ARAI T MANN D IWATSUBO T HISANAQA S GOEDERT M HASEQAWA M | 2007 | FEBS Lett2007，581，24： | 1 |
| 18 | Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implica tions for cell based vascular therapy显示文摘 | Griese D P Ehsan A Melo L G Kong D Zhang L Mann M J | 2003 | Circulation2003，108，： | 1 |
| 19 | Cerebral amyloid angiopathy and de- mentia显示文摘 | Tian J Shi J Mann D M | 2004 | Panminerva Med2004，46，： | 1 |
| 20 | Feasibility study of using air as a contrast medium in MR colonography 显示文摘 | So AM Lam WW Mann D | 2003 | Clin Radiol2003，58，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员